{
  "num_tested_probands": [
    1,
    1,
    1,
    1,
    0
  ],
  "num_positive_het_probands": [
    0,
    0,
    0,
    0,
    0
  ],
  "positive_phenotypes": [
    [
      "Severe hepatopathy",
      "Neurological deterioration"
    ],
    [
      "Axial hypotonia",
      "Hyper-tonia",
      "Dystonic posturing of arms and legs",
      "Severe delay of cognitive and motor development",
      "Decreased awareness",
      "Lateral eye deviation",
      "Twitching of the eyelids at the left",
      "Hypoglycemia",
      "Motor hyperactivity",
      "Continuous choreatic movements",
      "Acute liver failure (ALF)",
      "Metabolic encephalopathy",
      "Severe generalized amyotrophy"
    ],
    [
      "Developmental delay",
      "Motor weakness",
      "Intellectual disability",
      "Seizures",
      "Epilepsy",
      "Acute liver failure",
      "Unconsciousness"
    ],
    [],
    []
  ],
  "num_compound_or_double_hets": [
    0,
    1,
    1,
    0,
    0
  ],
  "explanation": {
    "num_tested_probands": [
      "The proband was the only individual tested for genetic analysis.",
      "The proband was the only individual tested for genetic information.",
      "The proband was the only individual for whom genetic testing was reported.",
      "The proband was the only individual for whom genetic testing was reported.",
      "There is no information about the number of probands tested in this report."
    ],
    "num_positive_het_probands": [
      "No heterozygous proband was identified with a pathogenic variant.",
      "No heterozygous probands were identified with a pathogenic variant.",
      "No proband was heterozygous for a pathogenic variant.",
      "No proband was heterozygous for a pathogenic variant.",
      "There is no information about the number of positive heterozygous probands in this report."
    ],
    "positive_phenotypes": [
      "Severe hepatopathy and neurological deterioration were observed in the proband.",
      "Clinical phenotypes associated with the positive probands include axial hypotonia, hyper-tonia, dystonic posturing of arms and legs, severe delay of cognitive and motor development, decreased awareness, lateral eye deviation, twitching of the eyelids at the left, hypoglycemia, motor hyperactivity, continuous choreatic movements, acute liver failure (ALF), metabolic encephalopathy, and severe generalized amyotrophy.",
      "Clinical phenotypes associated with the proband included developmental delay, motor weakness, intellectual disability, seizures, epilepsy, acute liver failure, and unconsciousness. The presence of these phenotypes suggests that the proband has WARS2 deficiency.",
      "None of the phenotypes were explicitly mentioned in the report.",
      "There is no information about clinical phenotypes associated with positive probands in this report."
    ],
    "num_compound_or_double_hets": [
      "The proband did not have compound or double heterozygous mutations reported.",
      "One compound heterozygous variant was identified in the WARS2 gene.",
      "One compound heterozygote was reported in the family study.",
      "The proband was compound heterozygous for two mutations, but this information is not explicitly stated in the report.",
      "There is no information about compound or double heterozygous mutations in this report."
    ],
    "report": [
      "This report describes a 6-year-old girl with mitochondrial tryptophanyl-tRNA synthetase deficiency, who presented with severe hepatopathy and neurological deterioration after starting valproate treatment."
    ],
    "explanation": [
      "The proband had a deficient activity of complex III and low normal activities of complexes I and IV. Complex V has two subunits that are encoded by the mtDNA, which can detach from the holo-complex if not synthesized in the mitochondrial matrix.",
      "The report does not provide explicit information on the number of positive HET probands or the phenotypes associated with them. However, it mentions that the proband had a mosaic pattern after activity staining of cytochrome c oxidase and exhibited hepatopathy after valproate treatment."
    ]
  }
}